Skip to navigation Skip to content
Masterclass Hub
  • Twitter
  • LinkedIn
  • Home
    • About
    • Objectives
    • Why Join
    • Testimonials
  • 2022 Series
    • Up-coming Events
    • On-Demand Events
      • Collaborating on payment models to unlock the potential of multi-indication therapies.
      • Severity in value assessment: from principle to practice
    • Contributors
  • Knowledge Hub
  • On-demand tickets
    • 2021
      • About 2021 Series
      • On-demand tickets
      • Contributors
      • Knowledge Hub
  • Sponsorship
  • About
    • About OHE
    • Events
  • Login
  • Home
    • About
    • Objectives
    • Why Join
    • Testimonials
  • 2022 Series
    • Up-coming Events
    • On-Demand Events
      • Collaborating on payment models to unlock the potential of multi-indication therapies.
      • Severity in value assessment: from principle to practice
    • Contributors
  • Knowledge Hub
  • On-demand tickets
    • 2021
      • About 2021 Series
      • On-demand tickets
      • Contributors
      • Knowledge Hub
  • Sponsorship
  • About
    • About OHE
    • Events
  • Login
  • £0.00 0 items

Category: Blog

Search the Knowledge Hub

Orphan Drugs Policies: A Suitable Case for Treatment

  • #Blog,
  • #Innovation for Small Populations,

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Martina Garau and Anna Bucsics
  • #Blog,
  • #Innovation for Small Populations,

Recent Statistics on Orphan Approvals in Scotland and England

Martina Garau
  • #Blog,
  • #Innovation for Small Populations,

An analysis of orphan medicine expenditure in Europe: is it sustainable?

Jorge Mestre-Ferrandiz, Christina Palaska, Tom Kelly, Adam Hutchings, Adam Parnaby 
  • #Blog,
  • #Innovation for Small Populations,

Why are Patients in Need Not Getting Early Access to Life-Changing Medicines?

Hannah Schirrmacher, Isobel Firth and Grace Hampson
  • #Adaptive Pathways,
  • #Blog,

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

Firth, I., Schirrmacher, H., Hampson, G. and Towse, A.
  • #Adaptive Pathways,
  • #Blog,
  • #One-time Therapies,

Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK

Bernarda Zamora
  • #Adaptive Pathways,
  • #Blog,
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

Article by: Lotte Steuten, Eleanor Bell & Margherita Neri
  • #Blog,
  • #Exploring Value,
  • #The broader value of vaccines,
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Simon Brassel, Margherita Neri & Lotte Steuten
  • #Blog,
  • #Exploring Value,
  • #The broader value of vaccines,
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Bernarda Zamora and Adrian Towse
  • #Blog,
  • #Capturing multiple dimensions of value in decision making,
  • #Exploring Value,

NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study

Nancy Devlin, Koonal Shah, Yan Feng
  • #Blog,
  • #Patient Outcomes,

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Chris Sampson
  • #Blog,
  • #Patient Outcomes,

Adult Versus Adolescent Preferences for EQ-5D-Y Health States

Koonal Shah
  • #Blog,
  • #Patient Outcomes,

End of Life Treatments, Societal Values, and ‘Overall’ Preference

Koonal Shah
  • #Blog,
  • #Patient Outcomes,

Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA

Koonal Shah
  • #Blog,
  • #Patient Outcomes,

Two New Papers on EQ-5D-5L Valuation in Ireland

Koonal Shah
  • #Blog,
  • #Patient Outcomes,

A New Online Tool for Creating Personal and Social EQ-5D-5L Value Sets

Nancy Devlin
  • #Blog,
  • #Patient Outcomes,

Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Mott, D.
  • #Blog,
  • #HTA,
  • #Patient Preference,
  • #Patient Voice,

Comparing Preference-based Outcome Measures for Overactive Bladder: EQ-5D-5L vs OAB-5D

Herdman, M., Nazir, J., Hakimi, J., Siddiqui, E., Huang, M., Pavesi, M., MacDiamid, S., Drake, M.J., and Devlin, N
  • #Blog,
  • #Patient Outcomes,

A New Way of Presenting Health States in Valuation Studies

Cole, A., Shah, K., Mulhern, B., Feng, Y. and Devlin, N
  • #Blog,
  • #Patient Outcomes,

Effect of Religion on the Perception of Health States: A Qualitative Study

Elbarazi, I., Devlin, N.J., Katsaiti, M.S., Papadimitropoulos, E.A., Shah, K.K. and Blair, I.
  • #Blog,
  • #Patient Outcomes,

Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L

Lorgelly, P.K., Doble, B., Rowen, D. Brazier, J
  • #Blog,
  • #Patient Outcomes,

The Application of Anchoring Vignettes to the EQ-5D-5L: A Possible Solution to Reporting Heterogeneity in PROMs

Paula Lorgelly
  • #Blog,
  • #Patient Outcomes,
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

  • #Blog,
  • #Broader value of other interventions,
  • #Exploring Value,

5 Things You Should Do with EQ-5D Data

Nancy Devlin
  • #Blog,
  • #Patient Outcomes,
An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

  • #Blog,
  • #Capturing multiple dimensions of value in decision making,
  • #Exploring Value,

Adjusting Patient Case Mix to Compare PROMs across Providers

Nuttall, D., Parkin, D. and Devlin, N
  • #Blog,
  • #Patient Outcomes,
Using MCDA to Assess the Value of Treatments for Rare Diseases

Using MCDA to Assess the Value of Treatments for Rare Diseases

  • #Blog,
  • #Exploring Value,
  • #The use of multi-criteria decision analysis (MCDA),
OHE logo
Bespoke events:
events@ohe.org
  • Terms and Conditions
  • Privacy Policy
  • Contact us
  • Get Technical Assistance

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT.

Get Technical Assistance